Lab21 introduces new immunodiagnostic system to market

Lab21 has announced the launch of its latest scientific product – the high-sensitivity immunodiagnostic system for the detection of cytomegalovirus (CMV) antibodies in human serum or plasma.

The release of the equipment marks the expansion of the firm’s diagnostic and blood-banking products portfolio.

According to the firm, the assay is noticeably more sensitive than others currently available, making it capable of detecting potential CMV infections earlier.

This, in turn, it states, offers greater assurance that a blood sample is not infected, minimising the risk of blood-borne transmissions.

“We expect this pipeline to continue to provide a regular supply of new in vitro diagnostic (IVD) products which will rapidly establish Lab21 as a significant presence in the global IVD market,” commented Graham Mullis, chief executive officer of Lab21.

Lab21, which is headquartered in Cambridge, provides diagnostic products and services to healthcare, pharmaceutical and biotechnology companies worldwide.